Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Blood

Volumn 123, Issue 3, 2014, Pages 317-325

  Mahlangu, Johnny ^a   Powell, Jerry S ^b   Ragni, Margaret V ^c   Chowdary, Pratima ^d   Josephson, Neil C ^e   Pabinger, Ingrid ^f   Hanabusa, Hideji ^g   Gupta, Naresh ^h   Kulkarni, Roshni ⁱ   Fogarty, Patrick ^j   Perry, David ^k   Shapiro, Amy ^l   Pasi, K John ^m   Apte, Shashikant ⁿ   Nestorov, Ivan ^o   Jiang, Haiyan ^o   Li, Shuanglian ^o   Neelakantan, Srividya ^o   Cristiano, Lynda M ^o   Goyal, Jaya ^o   Sommer, Jurg M ^o   Dumont, Jennifer A ^o   Dodd, Nigel ^o   Nugent, Karen ^o   Vigliani, Gloria ^o   Luk, Alvin ^o   Brennan, Aoife ^o   Pierce, Glenn F ^o   more..

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e PUGET SOUND BLOOD CENTER   (United States)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g Ogikubo Hospital   (Japan)

^h MAULANA AZAD MEDICAL COLLEGE   (India)

ⁱ MICHIGAN STATE UNIVERSITY   (United States)

^j HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^k ADDENBROOKE S HOSPITAL   (United Kingdom)

^l INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^m QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁿ Department of Hematology   (India)

^o BIOGEN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOSTATIC AGENT; HYBRID PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT FACTOR VIII FC FUSION PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANNUALIZED BLEEDING RATE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD CLOTTING PARAMETERS; CHILD; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACE INJURY; FAINTNESS; FEMUR FRACTURE; FEVER; HEMARTHROSIS; HEMOPHILIA A; HUMAN; HYPERTENSION; INFLUENZA; INGUINAL HERNIA; LUMBAR SPINAL STENOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MYALGIA; NEPHROLITHIASIS; PERIOPERATIVE PERIOD; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SCHOOL CHILD; TACHYCARDIA; THROMBOSIS; TOOTH DISEASE; UPPER RESPIRATORY TRACT INFECTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893123337     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-529974     Document Type: Article

References (29)

1. Fogarty PF. Biological rationale for new drugs in the bleeding disorders pipeline. Hematology Am Soc Hematol Educ Program 2011; 2011: 397-404.
2. Rath T, Baker K, Dumont J.A., et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics [published online ahead of print October 24, 2013]. Crit Rev Biotechnol.
3. National Hemophilia Foundation. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx? menuid557&contentid51007. Accessed July 18, 2013.
4. Lillicrap D. Improvements in factor concentrates. Curr Opin Hematol. 2010; 17(5): 393-397.
5. Lillicrap D. Improvements in factor concentrates. Curr Opin Hematol. 2010; 17(5): 393-397. (Pubitemid 32677658)
6. Peters RT, Toby G, Lu Q., et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost. 2013; 11(1): 132-141.
7. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7(9): 715-725. (Pubitemid 47327396)
8. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia a patients. Blood. 2012; 119(13): 3031-3037.
9. European Medicines Agency. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/ 08/WC500109692.pdf. Accessed July 18, 2013.
10. United States Food and Drug Administration. Guidance for industry: assay development for immunogenicity testing of therapeutic proteins. Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM192750.pdf. Accessed July 18, 2013.
11. Clopper CJ, Pearson E. The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika. 1934; 26: 404-413.
12. Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012; 119(12): 2922-2934.
13. Margaglione M, Castaman G, Morfini M., et al.; AICE-Genetics Study Group. The Italian AICE-Genetics hemophilia a database: results and correlation with clinical phenotype. Haematologica. 2008; 93(5): 722-728. (Pubitemid 351669312)
14. Miller CH, Benson J, Ellingsen D., et al.; Hemophilia Inhibitor Research Study Investigators. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia. 2012; 18(3): 375-382.
15. Valentino LA, Mamonov V, Hellmann A., et al.; Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia a management. J Thromb Haemost. 2012; 10(3): 359-367.
16. Recht M, Nemes L, Matysiak M., et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia. 2009; 15(4): 869-880.
17. Manco-Johnson M.J., Kempton CL, Reding M.T., et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose formulated recombinant factor VIII-FS in adults with severe hemophilia a (SPINART). J Thromb Haemost. 2013; 11(6): 1119-1127.
18. Terraube V, O'Donnell JS, Jenkins PV. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia. 2010; 16(1): 3-13.
19. Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008; 111(7): 3540-3545.
20. Dumont JA, Liu T, Low S.C., et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia a mice and dogs. Blood. 2012; 119(13): 3024-3030.
21. Mei B, Pan C, Jiang H., et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia a treatment. Blood. 2010; 116(2): 270-279.
22. Tiede A, Brand B, Fischer R., et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013; 11(4): 670-678.
23. Kumar S, Liu T, Kulman J.D., et al. Effect of unstructured polypeptide insertions on the recombinant expression of human factor VIII. International Society on Thrombosis and Haemostasis - 24th Congress; 2013; Amsterdam, Netherlands. J Thromb Haemost. 2013; 11(Suppl. 2): 711.
24. Gouw SC, van der Bom JG, Ljung R, et al.; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013; 368(3): 231-239.
25. Ingerslev J. FDA Workshop on factor VIII inhibitors held at the NIH, Bethesda, MA on 21 November 2003. Haemophilia. 2004; 10(3): 288-289. (Pubitemid 38584803)
26. Whelan SF, Hofbauer CJ, Horling F.M., et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia a patients. Blood. 2013; 121(6): 1039-1048.
27. Klintman J, Hillarp A, Donfield S., Berntorp E, Astermark J. Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A. Haemophilia. 2013; 19(1): 106-112.
28. Klintman J, Hillarp A, Berntorp E., Astermark J. Long-term anti-FVIII antibody response in Bethesda-negative haemophilia a patients receiving continuous replacement therapy. Br J Haematol. 2013; 163(3): 385-392.
29. Dimichele DM, Blanchette V, Berntorp E. Clinical trial design in haemophilia. Haemophilia. 2012; 18(SUPPL. 4): 18-23.